secwatch.observer — SEC 8-K summary
======================================

Issuer:     Royalty Pharma plc (RPRX)
CIK:        0001802768
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001193125-23-004274
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Royalty Pharma expects 2022 Adj. Cash Receipts ~$2.79B, at upper end of guidance; 31% YoY growth
--------------------------------------------------------------------------------

- 2022 Adjusted Cash Receipts (non-GAAP) expected ~$2,785-2,790M, towards upper end of $2,750-2,800M guidance; 31% YoY growth.
- 2022 GAAP operating cash flow expected ~$2,140-2,150M.
- Since 2020, announced $10B in transactions; investments expected to add ~$1B to annual Adjusted Cash Receipts in 2025.
- Added royalties on six new therapies in 2022, including Trelegy (respiratory), olpasiran, aficamten, and MK-8189.
- Capital deployment target $10-12B over five years; potential to double to $4-5B annually longer term.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802768/000119312523004274/0001193125-23-004274-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802768/000119312523004274/d446015d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-004274

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer